Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) to enable high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Researchers achieved a 3.38 Å cryo-EM structure, with just 4 days from gene assembly to sample preparation for cryo-EM
Published on bioRxiv, findings show potential for accelerating structural biology research, with 12 additional GPCR targets produced and purified
Cambridge, UK, and Boston, MA, USA, 17 November 2026: Nuclera, the biotechnology company enabling access to…
Collaboration with Biogen will leverage TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases.
Includes up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties.
Cambridge, UK, 16 November 2026: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic…
Launched on Monday, the new Vernalis website offers a fresh outlook and clear message of what Vernalis can deliver on behalf of its pharma and biotech partners.
Vernalis has been a long-standing name in the UK life sciences industry; but this new website emphasises what the company has evolved to become - a specialist HitID and integrated drug discovery service provider with the expertise and capabilities to take a small molecule target through to candidate selection. Please contact Vernalis via the website to find out more.
Drug Discovery CRO | Vernalis
Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development.
Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) is responsible for funding, sponsoring and executing a first-in-human Phase 1/2a clinical trial of DPTX8743, including Clinical Trial Application (CTA)-enabling studies. Dewpoint retains all rights to DPTX8743 and has the right to license the results and intellectual property arising from the…
New MCP server connects external AI tools directly to structured laboratory data, with no exports or custom integrations required
· Suite of AI functions address key data bottlenecks in biological research labs, from protocol writing to equipment set-up
· The launch also marks Lab Thread's incorporation in the United States, extending support for the company's growing base of US life sciences customers
Silverstone, UK, 10th November 2026: Lab Thread Ltd, a UK-based life science software company,…
Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patients
Announcement comes after a recent European Respiratory Journal viewpoint by Qureight CSO identifying fibrosis quantification as the key structural imaging biomarker needed for antifibrotic trials
PIPE-791 targets lysophosphatidic acid receptor 1 (LPAR1), a clinically validated target for IPF
Cambridge, UK, and San Diego, CA, 9 November 2026 – Qureight, an end-to-end…
Amsbio is a premier supplier of high-quality heparan sulfate (HS) monoclonal antibodies for use in brain and neurodegenerative research. In a recent published study** from Stanford University, these antibodies have been used to reveal a key role for endothelial glycocalyx degradation in aging and neurodegenerative disease.
Heparan sulfate is a highly sulphated polysaccharide, synthesized as the glycosaminoglycan component of heparan sulfate proteoglycans (HSPGs). Heparan Sulfate antibodies including clones 10E4, JM403, and 3G10 - serve as critical molecular tools and biomarkers in brain…
Sandwich, UK — 4 November 2026: Discovery Park, Kent’s science and innovation hub, has launched the eighth edition of its Discovery Spark accelerator programme, welcoming 10 startups to its campus in Sandwich.
The eighth cohort brings together 13 founders working across drug discovery, diagnostics, wound care, crop science and biotechnology. Startups were selected based on the need for their innovation, the uniqueness of their solution and the strength of their team. Throughout November, founders will attend specialist-led sessions in Kent and London focused on investor readiness. Topics…
The Budget on 28 October 2026, the first under the new Prime Minister and John Healey’s first as Chancellor, left the rates of R&D tax relief unchanged and announced two changes to how claims are made. Companies making R&D claims on or after 1 April 2027 will no longer have to submit a Claim Notification Form, and the Additional Information Form will be simplified from autumn 2027. Alongside the Budget, HM Treasury opened a consultation on simplifying the corporate tax rules, R&D relief among them.
As with any Budget, there will be winners and losers. For R&D tax relief, the…
Bidwells' Creative Places team has appointed Sue Foxley and Harry Blevins, strengthening its research capability and London science and technology leasing offer as the business continues to grow.
Sue will be joining the Creative Places team on a part-time basis, to focus on leading edge research and data trends in science and technology as well as providing valuable insight to clients on ecosystem strategy through Creative Places consultancy mandates. Sue will continue to lead the Research function across the Bidwells Group.
Harry will also join the Creative Places team on a full-time…